35.MackieI,LangleyK,ChitolieA,etal.DiscrepanciesbetweenADAMTS13recurrentthromboticthrombocytopenicpurpura.Haematologica.2012;
activityassaysinpatientswiththromboticmicroangiopathies.Thromb97(2):297-303.
Haemost.2013;109(3):488-496.40.ShahN,RutherfordC,MatevosyanK,ShenYM,SarodeR.Roleof
36.WuN,LiuJ,YangS,etal.DiagnosticandprognosticvaluesofADAMTS13inthemanagementofthromboticmicroangiopathiesin-
ADAMTS13activitymeasuredduringdailyplasmaexchangetherapycludingthromboticthrombocytopenicpurpura(TTP).BrJHaematol.
inpatientswithacquiredthromboticthrombocytopenicpurpura.2013;163(4):514-519.
Transfusion.2015;55(1):18-24.41.ThomasMR,deGrootR,ScullyMA,CrawleyJT.PathogenicityofAnti-
37.JolyB,StepanianA,HajageD,etal.EvaluationofachromogenicADAMTS13AutoantibodiesinAcquiredThromboticThrombocyto-
commercialassayusingVWF-73peptideforADAMTS13activitypenicPurpura.EBioMedicine.2015;2(8):942-952.
measurement.ThrombRes.2014;134(5):1074-1080.42.RiegerM,MannucciPM,KremerHovingaJA,etal.ADAMTS13au-
38.AyanambakkamA,KremerHovingaJA,VeselySK,GeorgeJN.Di-toantibodiesinpatientswiththromboticmicroangiopathiesandother
agnosisofthromboticthrombocytopenicpurpuraamongpatientswithimmunomediateddiseases.Blood.2005;106(4):1262-1267.
ADAMTS13Activity10%-20.AmJHematol.2017;92(11):E644-E646.43.RooseE,SchelpeAS,JolyBS,etal.Anopenconformationof
39.Froehlich-ZahndR,GeorgeJN,VeselySK,etal.EvidenceforaroleofADAMTS-13isahallmarkofacuteacquiredthromboticthrombocy-
anti-ADAMTS13autoantibodiesdespitenormalADAMTS13activityintopenicpurpura.JThrombHaemost.2018;16(2):378-388.
538AmericanSocietyofHematology |
|
